Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

GSK, Chroma Therapeutics form alliance
August 2009
SHARING OPTIONS:

LONDON—GlaxoSmithKline PLC and British compatriot Chroma Therapeutics Ltd. announced in July that they will co-develop macrophage-targeted compounds using Chroma's proprietary esterase-sensitive motif (ESM) technology, which adds amino acid esters to compounds, with the aim of targeting the compounds to specific cells in the inflammatory disease process. Chroma will be responsible for four discovery and development programs to identify small-molecule therapeutics, including its macrophage-targeted HDAC inhibitor program for inflammatory disorders such as rheumatoid arthritis, through completion of clinical proof-of-concept studies. GSK may elect to obtain an exclusive, worldwide license to product candidates within the program. Chroma will retain full rights to further develop and commercialize its product candidates in any program GSK chooses not to license. Chroma will receive an upfront cash payment, milestone payments, option fees and tiered royalties that could exceed $1 billion.
 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.